Company profile
Mineralys Therapeutics, Inc.
Pipeline1 asset
- lorundrostatMLS-101 / Aldosterone synthase (CYP11B2) / Small molecule / Cardio-Renal-Metabolic SyndromeUncontrolled and treatment-resistant hypertensionPhase 3CompletedGlobalObstructive Sleep Apnea (OSA) and HypertensionPhase 2OngoingGlobalChronic Kidney Disease (CKD)Phase 2OngoingGlobal
Latest news22 items
All newsMineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026)
Presentation / Abstract • Phase 3Late-breaking poster presentation Sun, Jun 14, 2026, 10:00 AM EDT
Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)
Presentation / Abstract • Phase 3Late-breaking poster presentation Sun, Jun 14, 2026, 9:00 AM CT
Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
Presentation / Abstract • Phase 3ESH 2026 presentation Sat, May 30, 2026, 11:15 AM EDT
Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
Presentation / Abstract • Phase 3Oral presentation Sat, May 30, 2026, 5:15 PM CEST